Galectin Therapeutics Inc. (GALT)

[vein]

Letting some air out today !!

[vein]

But I had 20,000 !!!

[TrendTrade2016]

AND AT 2.45...YA GOT ME BEAT BIG TIME!

[TrendTrade2016]

ONLY...LOL...I ONLY HAVE A 1000..NICE WORK CHAMP!!

[vein]

Man , I only bought 5000 shares at 1.20 . Happy but I should have loaded the boat a bit more.

[TrendTrade2016]

GALT...THESE BIO BEAST OF THE BIO MARKET

[Retire43]

https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade

[Retire43]

Hey look at this;
GALT shareholders!
If you want an alternative to or additionally own a Galectin drug by the creator of Galectin antagonist, Dr Platt the father of the new science glycovirlogy

Viruses
Cancer
And hypoxia drug! BXT 25

https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade

[TrendTrade2016]

GALT..THE BIO BEAST THAT KEEPS BEASTING...

[TrendTrade2016]

GALT the bio beast of the bio techs

[Monksdream]

GALT new 52 hi

[TrendTrade2016]

GALT BREAKING OUT

[TrendTrade2016]

Play the chart not the story and sell before news

[vein]

What do we think this run is credited to ?? Our data readout isn’t until Q4??

[TrendTrade2016]

GALT WEEKLY BREAK OUT HERE IS STRONG

[Monksdream]

GALT new 52 hi

[TrendTrade2016]

GALT BIO BEAST!!!

[vein]

Just trying to justify the run here. I’m happy of course , my entry was 1.20

[Monksdream]

So sell short

[vein]

With no news , trial results not for a long time

[Monksdream]

GALT new 52 hi

[vein]

Hmmm could be

[Monksdream]

Professional asset manager support

[vein]

Wonder why we have such positive movement here ???

[Monksdream]

GALT under $3

[Glycobio]

In any case, setting aside the noise, the most important thing is that this is the only drug candidate in a late stage clinical trial which has the potential to address a fatal complication of NASH cirrhosis. The excess galectin-3 in the disease process increases fibrotic activity and portal hypertension. GALT's galectin-3 inhibitor, belapectin, is a large chain carbohydrate compound that has side chains that are similar to the natural galectin-3 ligand, and inhibits the excess galectin-3 produced by macrophages in the liver. Since the body can metabolize this carbohydrate compound without relying on the liver, it does not put extra strain on the liver, which is why they had good results recently from the 4th data safety monitoring board (unlike competitors who keep running into safety issues with their liver drugs). When this galectin-3 pathway disease process is kept in check, it stabilizes portal hypertension, with the goal of reducing the formation of esophageal varices that develop from excess portal hypertension. Many cirrhosis patients die from bleeding varices. GALT could potentially offer a breakthrough treatment for the subgroup of patients who have not developed varices yet, by repeating prior phase 2 results in this phase 2/3 adaptive trial. As an investment it is very interesting because the stock price is so low right now compared to the risk/reward which I think is pretty good. If successful with the next readout the market cap could jump to billions.

By the way I have zero connection with the company or anyone associated with the company. I have an interest in glycobiology research which is why I study these topics in depth. I randomly came across this inverstorshub board and noticed a lot of misinformation or misguided info here so I figured I'd pitch in with some knowledge.

[sunspotter]

You’re right about Nasdaq. Sorry.

I will edit my post to omit the incorrect statement that GALT is an OTC stock.

[Glycobio]

That is factually false. Not sure where you are getting your information from. GALT has been on NASDAQ for many years now (more than 10 years?) although yes they started small, like many other companies start small back when they were a team of Harvard and Weizmann Institute researchers. How can you hold it against them that they started small more than 10 years ago.

As far as the founder, I think you're referring to Jim who played a role in venture capital financing but otherwise his role has been very limited, especially since 2018 when he had a disagreement with Traber as the CEO he stepped into the background and faded away. And now he was even replaced by Dr. Ben Carson as a board member, so he's not even on the board of directors anymore.

You like to bring up irrelevant things.

[sunspotter]

I posted wrong information so I’ve edited this post.

Still think Ben Carson as a Board Director is the reddest of red flags, though.

[Glycobio]

You're looking at ancient history 20 years ago? The company started with research from Harvard and Weizmann Institute of Science in galectin inhibitors. Employees of the company wrote the authoritative book on Galectins in 2008 (Wiley). Yes they were acting like a startup company in the very beginning which means mistakes, but the drug development is very serious and patients have now started to enter Phase 3 in a global trial for cirrhosis where there are no currently approved drugs yet, which is a major accomplishment to get this far.

[sunspotter]

“ Dr. Ben Carson is an advisor and recently joined as a board member. ”

If GALT (previously known as PRWP)’s long history of misrepresentation and failure hasn’t already scared off any thinking person, this appointment should do the trick.

[Glycobio]

This is the only company in a late stage clinical trial for advanced liver disease which as a clinical outcome endpoint (prevention of varices, an often fatal complication). The galectin-3 inhibitor is also showing good results for cancer immunotherapy.

The CEO of GALT takes 80% pay in shares and the Chairman is a multi billionaire financial backer of the company who buys tens of millions in GALT stock periodically.

Dr. Ben Carson is an advisor and recently joined as a board member.

The heavy insider buying is a good sign.

[Glycobio]

There is a lot of spam here from other companies trying to get some attention, that has nothing to do with GALT.

[Retire43]

Look at this reprint! Share this.

https://www.preprints.org/manuscript/202309.0077/v1

[sunspotter]

LOL!

Somewhere in that breathless ridiculous spiel there should be a big disclaimer. I wonder how many free shares it cost?

PRWP may have changed its name and ticker, but it’s still a palpable scam. This leopard never changed its (fraudulent) spots.

Look for the big dump on any volume that absurd pimp piece generates.

[Retire43]

https://www.globenewswire.com/news-release/2023/08/24/2731222/0/en/Bioxytran-Announces-FDA-Clearance-of-its-IND-Application-for-ProLectin-M-in-Clinical-Trials.html

[vein]

Pretty quiet board for a stock that is on the move !!!!!

[Retire43]

Another interview :

https://www.proactiveinvestors.com/companies/news/1005615/bioxytran-drug-candidates-prolectin-m-and-prolectin-i-progressing-as-covid-19-treatments-1005615.html

[Retire43]

WTch this interview about Galectin inhibitors!

https://www.dropbox.com/s/l1d2v2nshekgdj1/bioxytran.mp4?dl=0

[vein]

I got 15000 shares at 1.30. But I wanted more but now don’t want to chase it !!

[BIGT80]

Hope you started a position! Don’t listen to anyone other than your own DD!

[vein]

Volume is staggering today !!

[vein]

Looks like our CEO got paid in shares again today !!

[sunspotter]

He is a founder of PRWP, GALT’s previous (crooked) incarnation.

[BIGT80]

Correct he is on the Board of Directors and founder of the 10x fund. The 10x fund does a fair amount of selling throughout the year. Obviously this is small cap bio which comes with with heavy risk. I will however say the current share price is so low it’s kind of an easy swing at a minimum.

[sunspotter]

Jim Czirr. Founder and current Director.

[BIGT80]

It a different management team than before.

[vein]

Thanks sun. I guess I should tread lightly here . I was going to add more shares Monday . Not so sure now .

[sunspotter]

Here’s a post from the great erniewerner to give you an idea of the shenanigans Jim Czirr and his cohorts engaged in:

Follow along with me and at the end you will understand why this company gives me indigestion. Here is the company's corporate presentation which was an SEC filing in Sep of last year.

http://www.sec.gov/Archives/edgar/data/1133416/000119312511259396/d237073dex991.htm

First, scroll down to p. 35 and make note of the 4 drug candidates for fibrosis. We have GM-CT-01 (Davanat), GM-CT-02, GR-MD-01, and GR-MD-02. GR-MD-02 is the drug candidate they plan to take into clinical trials next year for fatty liver disease.

Now scroll up to p. 15 on the same corporate presentation filed with the SEC. Look at the picture on the lower right, "Regression of Fibrosis after 4 weeks of treatment with GR-MD-01."

This picture is apparently the result of preclinical work done with GR-MD-01, a predecessor to the drug GR-MD-02. As mentioned, GR-MD-02 is the drug being taken into trials next year.

That same picture of GR-MD-01 results was part of a June 2011 Equity Research Report (p. 15) commissioned by GALT.

http://www.scribd.com/doc/42644034/Galectin-Therapeutics-Equity-Research-Report

Then on Dec 19, 2011 the company issued an update. Please take note of the picture on the left column labeled "Regression of Fibrosis after 4 weeks of treatment with GR-MD-02."

http://www.businesswire.com/news/home/20111219005344/en/Galectin-Therapeutics-Corporate-Update

Then on the company slide presentation filed with the SEC in April 2012 check p.22.

http://www.faqs.org/sec-filings/120411/PRO-PHARMACEUTICALS-INC_8-K/d332424dex991.htm

"Treatment with GR-MD-02 for four weeks shows dramatic regression of fibrosis."

If it is not obvious to you this is what I see. Multiple times in 2011 the company publishes a picture that is evidence of the efficacy of their drug GR-MD-01. Then, starting in Dec 2011, they continue using the same picture, but now attribute it to the effect of their drug GR-MD-02. Honest mistake? Typo? If you are really generous, you may choose to give them the benfit of the doubt. As a potential investor, I see it as a continueing pattern.

[sunspotter]

No. Like renowned sadly late poster erniewerner I take an interest in biotech scams.

Here’s a hint to show how much - or how little - has changed since the PRWP data falsification days:

James C. Czirr
Director since February 2009, Executive Chairman from February 2010 to January 2016, Co-Founder in 2000